

Figure 3. The hESC-Derived HBCs Were Characterized

(A and B) The hESCs (H9) were differentiated according to Figure 1A and then passaged onto a human LN111-coated dish. The attached cells (hESC-derived HBCs [HBC P0]) were collected at 15 min after plating. The percentage of AFP-positive, ALB-positive, CK7-positive, CK19-positive (A), and integrin $\alpha 6$ - and integrin $\beta 1$ -double positive (B) cells in the hESC-derived HBC P0, HBC P1 (HBCs passaged once), and HBC P10 (HBCs passaged ten times) populations was estimated by using FACS analysis. Data represent the mean \pm SD from seven independent experiments.

(legend continued on next page)



DISCUSSION

The main purpose of this study was to establish and characterize expandable HBCs from hPSCs. First, we identified that human LN111 could support self-renewal and proliferation of hPSC-derived HBCs in the presence of HGF and EGF. Second, we showed that the hPSC-derived HBCs have the potential to segregate into both hepatic and biliary lineages, and to integrate into the mouse liver parenchyma.

We have demonstrated that the hPSC-derived HBCs could be maintained on a human LN111-coated dish in an integrin $\alpha 6$ - and $\beta 1$ -dependent manner (Figure 1). It is known that undifferentiated hPSCs could be maintained on a human LN511-coated dish but not on a human LN111-coated dish (Rodin et al., 2010). This might suggest that human LN111 has the potential not only to selectively maintain HBCs, but also to eliminate residual undifferentiated cells. Our hepatoblast-like cells could efficiently proliferate for more than 3 months on a human LN111-coated dish (Figure 2). In the human liver development (during 5–10 weeks gestation), laminin is observed in both the perisinusoidal space and portal tracts (Couvelard et al., 1998). The expression of laminin is localized around the periportal biliary trees during the later stage of liver development (Couvelard et al., 1998). Hepatic stem cells reside around the hepatic portal area (Clément et al., 1988). It is also known that laminin is accumulated around oval cells although laminin is not expressed around quiescent mature hepatocytes (Paku et al., 2001). These facts suggest that laminin plays an important role in the maintenance and proliferation of hepatoblasts.

The hPSC-derived HBC P10 and clone were positive for hepatoblast markers (AFP, ALB, CYP3A7, and I-CAM), but negative for hepatic stem cell markers (N-CAM and Claudin 3) (Figure 3) (Schmelzer et al., 2007). Although the hPSC-derived HBCs were able to expand on human LN111-coated dish, Schmelzer et al. showed that human hepatoblasts do not proliferate under a monolayer culture condition, but human hepatic stem cells could self-replicate for more than 6 months (Schmelzer et al., 2007). Although further investigations of the hepatoblast characteristics in the hPSC-derived HBCs will be needed in the future, the results in the present study suggest that the characteristics of hPSC-derived HBCs expanded on human LN111-coated

dishes were similar to those in human hepatoblasts isolated from the human liver (Schmelzer et al., 2007; Zhang et al., 2008).

The hPSC-derived HBCs had the ability to integrate into the mouse liver parenchyma (Figure 5), in the manner of human hepatic stem cells or hepatoblasts (Schmelzer et al., 2007). The human ALB serum levels (approximately 20–70 ng/ml) in mice transplanted with the hESC-derived HBC P0 or HBC P10 were comparable to those in the previous paper in which the hESC-derived definitive endoderm cells, hepatoblasts, and hepatocyte-like cells were transplanted into mice (Liu et al., 2011), but were lower than those of human liver chimeric mice (Tateno et al., 2004). Human ALB serum levels would increase if more suitable host mice, such as urokinase plasminogen activator-SCID mice were used (Tateno et al., 2004).

In this study, we have developed a technology for the maintenance and proliferation of hPSC-derived HBCs by using human LN111. To transplant these cells for purposes of regenerative medicine, a xeno-free culture condition for hPSC-derived HBCs must be developed in the future. It is hoped that the hPSC-derived HBCs and their derivatives will be helpful in various medical applications, such as drug screening and regenerative medicine.

EXPERIMENTAL PROCEDURES

hESC and hiPSC Culture

The hESC lines (H1 [WA01] and H9 [WA09] [WiCell Research Institute]) and the hiPSC line, Dotcom (JCRB number: JCRB1327) (Makino et al., 2009; Nagata et al., 2009), were maintained on a feeder layer of mitomycin-C-treated mouse embryonic fibroblasts (Millipore) with ReproStem medium (ReproCELL) supplemented with 5 and 10 ng/ml fibroblast growth factor 2 (FGF2) (Katayama Kagaku Kogyo), respectively. H1 and H9 were used following the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science and Technology of Japan, and, furthermore, the study was approved by an independent ethics committee.

In Vitro Hepatoblast Differentiation

The differentiation protocol for the induction of definitive endoderm cells and hepatoblasts was based on our previous report with some modifications (Inamura et al., 2011; Takayama et al., 2012a, 2012b, 2013). In mesendoderm differentiation, hESCs/iPSCs were

(C–F) The gene expression levels of hepatic stem cell markers (C), pan-hepatoblast markers (D), hepatoblast markers (E), and mature hepatocyte (*CYP3A4*, *7A1*, *2C9*, and *T0*) or cholangiocyte markers (*integrin $\beta 4$* and *SOX9*) (F) were measured in the definitive endoderm cells, HBC P0, HBC P1, or HBC P10 by real-time RT-PCR.

(G) The gene expression levels of *CD13*, *CK7*, *DLK1*, and *PROX1* were measured in the hESC-derived definitive endoderm cells, HBC P0, HBC P1, or HBC P10 by real-time RT-PCR. Data represent the mean \pm SD from three independent experiments. Statistical significance was evaluated by ANOVA followed by Bonferroni post hoc tests to compare four groups (DE cells, HBC P0, HBC P1, and HBC P10). Groups that do not share the same letter are significantly different from each other ($p < 0.05$). DE, definitive endoderm cells.

See also Figures S2 and S3 and Tables S2–S4.




Figure 4. The hESC-Derived HBCs Could Differentiate into Both Hepatic and Biliary Lineages

(A) The procedure for differentiation of the hESC (H9)-derived HBC P0, HBC P10, or HBC clone into the hepatocyte-like cells is presented schematically. Details are described in Experimental Procedures.

(B) Phase-contrast micrographs of the HBC P10-derived hepatocyte-like cells are shown.

(C) The HBC P10-derived hepatocyte-like cells were subjected to immunostaining with anti-CYP3A4 (green), anti-αAT (red), and anti-ALB (red) antibodies.

(D and E) The gene expression levels of hepatocyte (D) or cholangiocyte (E) markers in HBC P0-, HBC P10-, or HBC clone-derived hepatocyte-like cells were measured by real-time RT-PCR after 14 days of hepatocyte differentiation. In (D), the gene expression levels in
(legend continued on next page)



cultured for 2 days on Matrigel (BD Biosciences) in differentiation hESF-DIF medium that contains 100 ng/ml Activin A (R&D Systems) (hESF-DIF medium was purchased from Cell Science & Technology Institute; differentiation hESF-DIF medium was supplemented with 10 μ g/ml human recombinant insulin, 5 μ g/ml human apotransferrin, 10 μ M 2-mercaptoethanol, 10 μ M ethanolamine, 10 μ M sodium selenite, and 0.5 mg/ml bovine fatty acid free serum albumin [all from Sigma]). To generate definitive endoderm cells, the mesendoderm cells (day 2) were transduced with 3,000 vector particle (VP)/cell of FOXA2-expressing adenovirus vectors (Ad-FOXA2) for 1.5 hr and cultured until day 6 on Matrigel in differentiation hESF-DIF medium supplemented with 100 ng/ml Activin A. For induction of hepatoblasts, the definitive endoderm cells were cultured for 3 days on a Matrigel in differentiation hESF-DIF medium supplemented with 30 ng/ml bone morphogenetic protein 4 (BMP4) (R&D Systems) and 20 ng/ml FGF4 (R&D Systems).

Establishment and Maintenance of the hPSC-Derived HBCs

The hPSC-derived HBCs were first purified from the hPSC-derived cells (day 9) by selecting attached cells on a human recombinant LN111 (BioLamina)-coated dish at 15 min after plating. The hPSC-derived HBCs were cultured on a human LN111-coated dish (2.0×10^4 cells/cm²) in maintenance DMEM/F12 medium (DMEM/F12 medium [Invitrogen] was supplemented with 10% FBS, $1 \times$ insulin/transferrin/selenium, 10 mM nicotinamide, 10^{-7} M dexamethasone (DEX) (Sigma), 20 mM HEPES, 25 mM NaHCO₃, 2 mM L-glutamine, penicillin/streptomycin, 40 ng/ml hepatocyte growth factor [HGF] [R&D Systems] and 20 ng/ml epidermal growth factors [EGF] [R&D Systems]). The medium was refreshed every day. The hPSC-derived HBCs were dissociated with Accutase (Millipore) into single cells and subcultured every 6 or 7 days.

Establishment and Maintenance of a Single hPSC-Derived HBC

For single-cell culture, the single HBC was plated to separate well of human LN111-coated 96-well plate in maintenance DMEM/F12

medium supplemented with 25 μ M Y-27632 (ROCK inhibitor) (Millipore), and then colonies derived from a single cell were manually picked up and cultured as well as HBCs (these cells were designated the HBC clone).

In Vitro Hepatocyte and Cholangiocyte Differentiation

To induce hepatocyte differentiation, the hPSC-derived HBC P0, HBC P10, and HBC clone were cultured for 14 days on a Matrigel-coated dish (7.5×10^4 cells/cm²) in HCM (Lonza) supplemented with 20 ng/ml HGF, 20 ng/ml Oncostatin M (OsM) (R&D Systems), and 10^{-6} M DEX. To induce cholangiocyte differentiation, the hPSC-derived HBC P0, HBC P10, and HBC clone were cultured in collagen gel for 14 days. To establish collagen gel plates, 500 μ l collagen gel solution (consisting of 400 μ l type I-A Collagen (Nitta gelatin), 50 μ l $10 \times$ DMEM, and 50 μ l of 200 mM HEPES buffer containing 2.2% NaHCO₃ and 0.05 M NaOH) was added to each well, and then the plates were incubated at 37°C for 30 min. The hPSC-derived HBC P0, HBC P10, and HBC clone (5×10^4 cells) were resuspended in 500 μ l differentiation DMEM/F12 medium (differentiation DMEM/F12 medium was supplemented with 20 mM HEPES, 2 mM L-glutamine, 100 ng/ml EGF, and 40 ng/ml insulin-like growth factor 2 [ILGF2]), and then mixed with 500 μ l of the collagen gel solution and plated onto the basal layer of collagen. After 30 min, 2 ml of differentiation DMEM/F12 medium was added to the well.

Ad Vectors

Ad vectors were constructed by an improved in vitro ligation method. The human EF-1 α promoter-driven FOXA2-expressing Ad vectors (Ad-FOXA2) were constructed previously (Takayama et al., 2012b). All of Ad vectors contain a stretch of lysine residue (K7) peptides in the C-terminal region of the fiber knob for more efficient transduction of hESCs, hiPSCs, mesendoderm cells, and definitive endoderm cells, in which transfection efficiency was almost 100%, and purified as described previously (Inamura

PH 48 hr were taken as 1.0. In (E), the gene expression levels in HBC P10 (before differentiation) were taken as 1.0. Data represent the mean \pm SD from three independent experiments. Student's t test indicated that gene expression levels of the hepatocyte markers in "after" were significantly higher than those in "before" ($p < 0.01$).

(F) The efficiency of hepatocyte differentiation was measured by estimating the percentage of ASGR1-positive cells using FACS analysis.

(G) The amounts of ALB (left) and urea (right) secretion were examined. Data represent the mean \pm SD from three independent experiments. Student's t test indicated that the percentage of ASGR1-positive cells, the ALB secretion level, and urea secretion level in "after" were significantly higher than those in "before" ($p < 0.01$).

(H) The procedure for the differentiation of the hESC-derived HBC P0, HBC P10, or HBC clone into cholangiocyte-like cells is presented schematically. Details are described in Experimental Procedures.

(I) Phase-contrast micrographs of the HBC P10-derived cholangiocyte-like cells are shown.

(J) The HBC P10-derived cholangiocyte-like cells were subjected to immunostaining with anti-CK7 (red) antibodies.

(K and L) The gene expression levels of hepatocyte (K) or cholangiocyte (L) markers in the HBC P0-, HBC P10-, or HBC clone-derived cholangiocyte-like cells were measured by real-time RT-PCR after 14 days of cholangiocyte differentiation. In (K), the gene expression levels in PH 48 hr were taken as 1.0. In (L), the gene expression levels in HBC P10 (before cholangiocyte differentiation) were taken as 1.0. Data represent the mean \pm SD from three independent experiments. Student's t test indicated that the gene expression levels of cholangiocyte markers in "after" were significantly higher than those in "before" ($p < 0.01$). "Before" indicates the HBCs before hepatocyte or cholangiocyte differentiation; "After" indicates the HBCs after hepatocyte or cholangiocyte differentiation.

See also Figures S4 and S5 and Tables S1–S4.




Figure 5. The hESC-Derived HBCs Were Integrated into the Mouse Liver Parenchyma

(A) The procedure for transplantation of the hESC (H9)-derived HBC P0 and HBC P10 into CCl₄ (4 ml/kg)-treated Rag2/IL2 receptor gamma double-knockout mice is presented schematically.

(B) The human ALB level in recipient mouse serum was measured at 2 weeks after transplantation. Data represent the mean ± SD from six to eight mice in each group. Statistical significance was evaluated by ANOVA followed by Bonferroni post hoc tests to compare all groups. Groups that do not share the same letter are significantly different from each other ($p < 0.05$).

(C) Expressions of the ALB (green) in the liver of transplanted mice were examined by immunohistochemistry at 2 weeks after transplantation.

(D and E) The expressions of AFP (red), ALB (green) (D), and αAT (red) (E) were examined by immunohistochemistry at 2 weeks after hESC-derived HBC P10 transplantation. White arrows show transplanted cells, which have double nuclei.

See also Tables S2 and S3.



et al., 2011; Takayama et al., 2011; Tashiro et al., 2010). The VP titer was determined by using a spectrophotometric method.

Flow Cytometry

Single-cell suspensions of the hPSC-derived cells were fixed with 4% paraformaldehyde (PFA) at 4°C for 10 min and then incubated with the primary antibody (described in Table S2), followed by the secondary antibody (described in Table S3). Control cells were incubated with anti-mouse, goat, or rabbit immunoglobulin (Ig) G antibodies (Santa Cruz Biotechnology) and then incubated with the secondary antibody. Flow cytometry analysis was performed using a fluorescence-activated cell sorting (FACS) LSR Fortessa flow cytometer (BD Biosciences). Cell sorting was performed using a FACS Aria (BD Biosciences).

RNA Isolation and RT-PCR

Total RNA was isolated from hPSCs and their derivatives using ISOGENE (Nippon Gene). cDNA was synthesized using 500 ng of total RNA with a Superscript VILO cDNA synthesis kit (Invitrogen). Real-time RT-PCR was performed with SYBR green PCR Master Mix (Applied Biosystems) using an Applied Biosystems StemOnePlus real-time PCR systems. Relative quantification was performed against a standard curve, and the values were normalized against the input determined for the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase. The primer sequences used in this study are described in Table S4. In addition, we confirmed that every beta integrin primer used in this manuscript showed a similar amplification efficacy (Table S5). The amplification efficiency was calculated from the slope of the standard curve according to the following formula: $e = 10^{-(1/\text{slope})-1}$. Every beta integrin primer used in this manuscript showed a similar amplification efficacy.

Immunohistochemistry

The cells were fixed with 4% PFA for 15 min and then blocked with PBS containing 2% FBS, 2% bovine serum albumin (BSA), and 0.1% Triton X-100 (Wako Pure Chemicals Industries) for 1 hr. The cells were incubated with primary antibody (described in Table S2) at 4°C for overnight, followed by incubation with a secondary antibody (described in Table S3) at room temperature for 1 hr. Nuclei were counterstained with DAPI (blue).

ELISA

The hPSC-derived HBC P0, HBC P10, and HBC clone were differentiated into the hepatocyte-like cells as described in Figure 4A. The culture supernatants, which were incubated for 24 hr after fresh medium was added, were collected and analyzed for the amount of ALB secretion by ELISA. ELISA kits for ALB were purchased from Bethyl Laboratories. The amount of ALB secretion was calculated according to each standard followed by normalization to the protein content per well. The human ALB amount in mice serum was also examined by ELISA.

Transplantation of the hESC-Derived HBCs

The hESC-derived HBCs were dissociated using accutase and then suspended with maintenance DMEM/F12 medium without serum.

Eight- to 10-week-old Rag2/IL2Rg double-knockout mice were prepared. The hESC-derived HBCs (1×10^6 cells) were transplanted 24 hr after administration of CCl₄ (4 ml/kg) by intrasplenic injection. Recipient mouse liver and blood were harvested at 2 weeks after transplantation. The livers were fixed with 4% PFA and processed for immunohistochemistry. Human hepatocytes producing the ALB, AFP, and α AT protein were identified in mouse liver by an antibody specifically recognizing human but not mouse albumin. In addition, serum was extracted and subjected to ELISA analysis. All animal experiments were conducted in accordance with institutional guidelines.

Urea Secretion

The hPSC-derived HBC P0, HBC P10, and HBC clone were differentiated into hepatocyte-like cells as described in Figure 4A. The culture supernatants, which were incubated for 24 hr after fresh medium was added, were collected and analyzed for the amount of urea secretion. The urea measurement kits were purchased from BioAssay Systems. The amount of urea secretion was calculated according to each standard followed by normalization to the protein content per well. In Figure S5B, both the HBC-derived hepatocyte-like cells and primary human hepatocytes (PHs) (three lots of cryopreserved human hepatocytes were used), that were cultured for 48 hr after the cells were plated (PH 48 hr), were cultured in HCM (containing glutamine) or DMEM (not containing glutamine; Wako) in the presence or absence of 1 mM ammonium chloride (NH₄Cl, Wako) for 24 hr, and then the amount of urea secretion was measured.

Primary Human Hepatocytes

Three lots of cryopreserved human hepatocytes (lot Hu8072 [CellzDirect], HC2-14, and HC10-101 [Xenotech]) were used. The vials of hepatocytes were rapidly thawed in a shaking water bath at 37°C; the contents of the vial were emptied into prewarmed Cryopreserved Hepatocyte Recovery Medium (Gibco) and the suspension was centrifuged at 100 g for 10 min at room temperature. The hepatocytes were seeded at 1.25×10^5 cells/cm² in HCM (Lonza) containing 10% fetal calf serum (FCS) (Gibco) onto type 1 collagen-coated 12-well plates. The medium was replaced with hepatocyte culture medium containing 10% FCS 6 hr after seeding. The hepatocytes, which were cultured 48 hr after plating the cells, were used in the experiments.

Adhesion-Blocking Assay Using Integrin Antibody

Twelve-well plates were coated with human recombinant LN111, 211, 411, or 511 (all from BioLamina) and blocked by 1% heat-denatured BSA containing PBS. The hESC-derived single cells were incubated with function-blocking antibodies to integrin α 6 and β 1 (at the concentrations as recommended by the manufacturer) for 30 min, plated on a human LN111-coated 12-well dish, and allowed to adhere for 1 hr at 37°C. After unattached cells were removed, the remaining adherent cells were fixed for 20 min with 5% glutaraldehyde. The hESC-derived cells that had adhered to the wells were stained with 200 μ l of 0.3% crystal violet (Wako) solution at room temperature for 15 min. Excess crystal violet was then removed, and the wells were washed three times. Fixed crystal violet was solubilized in 200 μ l of 100% ethanol at room



temperature for 15 min. Cell viability was estimated by measuring the absorbance at 595 nm of each well using a microtiter plate reader (Sunrise, Tecan).

CYP Activity

To measure the CYP1A2, 2C9, and 3A4 activity of the cells, we performed lytic assays by using P450-Glo™ CYP1A2, 2C9, and 3A4 Assay Kits (Promega), respectively. We measured the fluorescence activity with a luminometer (Lumat LB 9507; Berthold) according to the manufacturer's instructions. The CYP activity was normalized with the protein content per well.

Karyotyping

This experiment was carried out at Chromosome Science Labo.

Cell Viability Tests

Cell viability was assessed by using a WST-8 assay kit (Dojindo), and the results are presented in Figure S5C. After treatment with test compounds, such as acetaminophen (Wako) and troglitazone (Wako) for 24 hr, the cell viability was measured. The control cells were incubated in the absence of test compounds and were considered to have 100% viability value. Controls were treated with DMSO (final concentration 0.1%).

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and five tables and can be found with this article online at <http://dx.doi.org/10.1016/j.stemcr.2013.08.006>.

ACKNOWLEDGMENTS

We thank Yasuko Hagihara for her excellent technical support. H.M., K.K., and T.H. were supported by grants from the Ministry of Health, Labor, and Welfare of Japan. H.M. was also supported by the Project for Technological Development of the Japan Science and Technology Agency (JST) and by the Uehara Memorial Foundation. F.S. was supported by Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation. K.T. and Y.N. are Research Fellows of the Japan Society for the Promotion of Science.

Received: June 6, 2013

Revised: August 27, 2013

Accepted: August 27, 2013

Published: October 3, 2013

REFERENCES

Clément, B., Rescan, P.Y., Baffet, G., Loréal, O., Lehry, D., Champion, J.P., and Guillouzo, A. (1988). Hepatocytes may produce laminin in fibrotic liver and in primary culture. *Hepatology* 8, 794–803.

Couvelard, A., Binguier, A.F., Dauge, M.C., Nejari, M., Darai, E., Benifla, J.L., Feldmann, G., Henin, D., and Scoazec, J.Y. (1998). Expression of integrins during liver organogenesis in humans. *Hepatology* 27, 839–847.

Hay, D.C., Zhao, D., Fletcher, J., Hewitt, Z.A., McLean, D., Urruticoechea-Uriguen, A., Black, J.R., Elcombe, C., Ross, J.A., Wolf, R., and Cui, W. (2008). Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. *Stem Cells* 26, 894–902.

Inamura, M., Kawabata, K., Takayama, K., Tashiro, K., Sakurai, F., Katayama, K., Toyoda, M., Akutsu, H., Miyagawa, Y., Okita, H., et al. (2011). Efficient generation of hepatoblasts from human ES cells and iPSC cells by transient overexpression of homeobox gene HEX. *Mol. Ther.* 19, 400–407.

Kamiya, A., Kakinuma, S., Yamazaki, Y., and Nakauchi, H. (2009). Enrichment and clonal culture of progenitor cells during mouse postnatal liver development in mice. *Gastroenterology* 137, 1114–1126.

Liu, H., Kim, Y., Sharkis, S., Marchionni, L., and Jang, Y.Y. (2011). In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. *Sci. Transl. Med.* 3, 82ra39.

Makino, H., Toyoda, M., Matsumoto, K., Saito, H., Nishino, K., Fukawatase, Y., Machida, M., Akutsu, H., Uyama, T., Miyagawa, Y., et al. (2009). Mesenchymal to embryonic incomplete transition of human cells by chimeric OCT4/3 (POU5F1) with physiological co-activator EWS. *Exp. Cell Res.* 315, 2727–2740.

Nagata, S., Toyoda, M., Yamaguchi, S., Hirano, K., Makino, H., Nishino, K., Miyagawa, Y., Okita, H., Kiyokawa, N., Nakagawa, M., et al. (2009). Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells. *Genes Cells* 14, 1395–1404.

Paku, S., Schnur, J., Nagy, P., and Thorgeirsson, S.S. (2001). Origin and structural evolution of the early proliferating oval cells in rat liver. *Am. J. Pathol.* 158, 1313–1323.

Rodin, S., Domogatskaya, A., Ström, S., Hansson, E.M., Chien, K.R., Inzunza, J., Hovatta, O., and Tryggvason, K. (2010). Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. *Nat. Biotechnol.* 28, 611–615.

Schmelzer, E., Zhang, L., Bruce, A., Wauthier, E., Ludlow, J., Yao, H.L., Moss, N., Melhem, A., McClelland, R., Turner, W., et al. (2007). Human hepatic stem cells from fetal and postnatal donors. *J. Exp. Med.* 204, 1973–1987.

Sumi, T., Tsuneyoshi, N., Nakatsuji, N., and Suemori, H. (2008). Defining early lineage specification of human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin, Activin/Nodal and BMP signaling. *Development* 135, 2969–2979.

Takayama, K., Inamura, M., Kawabata, K., Tashiro, K., Katayama, K., Sakurai, F., Hayakawa, T., Furue, M.K., and Mizuguchi, H. (2011). Efficient and directive generation of two distinct endoderm lineages from human ESCs and iPSCs by differentiation stage-specific SOX17 transduction. *PLoS ONE* 6, e21780.

Takayama, K., Inamura, M., Kawabata, K., Katayama, K., Higuchi, M., Tashiro, K., Nonaka, A., Sakurai, F., Hayakawa, T., Furue, M.K., and Mizuguchi, H. (2012a). Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4 α transduction. *Mol. Ther.* 20, 127–137.

Takayama, K., Inamura, M., Kawabata, K., Sugawara, M., Kikuchi, K., Higuchi, M., Nagamoto, Y., Watanabe, H., Tashiro, K., Sakurai,



- F, et al. (2012b). Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1 α transduction. *J. Hepatol.* *57*, 628–636.
- Takayama, K., Kawabata, K., Nagamoto, Y., Kishimoto, K., Tashiro, K., Sakurai, F., Tachibana, M., Kanda, K., Hayakawa, T., Furue, M.K., and Mizuguchi, H. (2013). 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. *Biomaterials* *34*, 1781–1789.
- Tanimizu, N., Saito, H., Mostov, K., and Miyajima, A. (2004). Long-term culture of hepatic progenitors derived from mouse Dlk+ hepatoblasts. *J. Cell Sci.* *117*, 6425–6434.
- Tashiro, K., Kawabata, K., Inamura, M., Takayama, K., Furukawa, N., Sakurai, F., Katayama, K., Hayakawa, T., Furue, M.K., and Mizuguchi, H. (2010). Adenovirus vector-mediated efficient transduction into human embryonic and induced pluripotent stem cells. *Cell Reprogram.* *12*, 501–507.
- Tateno, C., Yoshizane, Y., Saito, N., Kataoka, M., Utoh, R., Yamasaki, C., Tachibana, A., Soeno, Y., Asahina, K., Hino, H., et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. *Am. J. Pathol.* *165*, 901–912.
- Zhang, L., Theise, N., Chua, M., and Reid, L.M. (2008). The stem cell niche of human livers: symmetry between development and regeneration. *Hepatology* *48*, 1598–1607.
- Zhao, D., Chen, S., Cai, J., Guo, Y., Song, Z., Che, J., Liu, C., Wu, C., Ding, M., and Deng, H. (2009). Derivation and characterization of hepatic progenitor cells from human embryonic stem cells. *PLoS ONE* *4*, e6468.

CCAAT/enhancer binding protein-mediated regulation of TGF β receptor 2 expression determines the hepatoblast fate decision

Kazuo Takayama^{1,2,3}, Kenji Kawabata⁴, Yasuhito Nagamoto^{1,2}, Mitsuru Inamura¹, Kazuo Ohashi⁵, Hiroko Okuno¹, Tomoko Yamaguchi⁴, Katsuhisa Tashiro⁴, Fuminori Sakurai¹, Takao Hayakawa⁶, Teruo Okano⁵, Miho Kusada Furue^{7,8} and Hiroyuki Mizuguchi^{1,2,3,9,*}

ABSTRACT

Human embryonic stem cells (hESCs) and their derivatives are expected to be used in drug discovery, regenerative medicine and the study of human embryogenesis. Because hepatocyte differentiation from hESCs has the potential to recapitulate human liver development *in vivo*, we employed this differentiation method to investigate the molecular mechanisms underlying human hepatocyte differentiation. A previous study has shown that a gradient of transforming growth factor beta (TGF β) signaling is required to segregate hepatocyte and cholangiocyte lineages from hepatoblasts. Although CCAAT/enhancer binding proteins (c/EBPs) are known to be important transcription factors in liver development, the relationship between TGF β signaling and c/EBP-mediated transcriptional regulation in the hepatoblast fate decision is not well known. To clarify this relationship, we examined whether c/EBPs could determine the hepatoblast fate decision via regulation of TGF β receptor 2 (TGFR2) expression in the hepatoblast-like cells differentiated from hESCs. We found that *TGFR2* promoter activity was negatively regulated by c/EBP α and positively regulated by c/EBP β . Moreover, c/EBP α overexpression could promote hepatocyte differentiation by suppressing TGFR2 expression, whereas c/EBP β overexpression could promote cholangiocyte differentiation by enhancing TGFR2 expression. Our findings demonstrated that c/EBP α and c/EBP β determine the lineage commitment of hepatoblasts by negatively and positively regulating the expression of a common target gene, *TGFR2*, respectively.

KEY WORDS: Hepatoblasts, c/EBP, CEBP, Human ESCs

INTRODUCTION

Many animal models, such as chick, *Xenopus*, zebrafish and mouse, have been used to investigate the molecular mechanisms of liver development. Because many functions of the key molecules in liver

development are conserved in these species, studies on liver development in these animals can be highly informative with respect that in humans. However, some functions of important molecules in liver development might differ between human and other species. Although analysis using genetically modified mice has been successfully performed, it is not of course possible to perform genetic experiments to elucidate molecular mechanisms of liver development in human. Pluripotent stem cells, such as human embryonic stem cells (hESCs), are expected to overcome some of these problems in the study of human embryogenesis, including liver development, because the gene expression profiles of this model are similar to those in normal liver development (Agarwal et al., 2008; DeLaForest et al., 2011).

During liver development, hepatoblasts differentiate into hepatocytes and cholangiocytes. A previous study has shown that a high concentration of transforming growth factor beta (TGF β) could give rise to cholangiocyte differentiation from hepatoblasts (Clotman et al., 2005). To transmit the TGF β signaling, TGF β receptor 2 (TGFR2) has to be stimulated by TGF β 1, TGF β 2 or TGF β 3 (Kitisin et al., 2007). TGF β binding to the extracellular domain of TGFR2 induces a conformational change, resulting in the phosphorylation and activation of TGFR1. TGFR1 phosphorylates SMAD2 or SMAD3, which binds to SMAD4, and then the SMAD complexes move into the nucleus and function as transcription factors to express various kinds of differentiation-related genes (Kitisin et al., 2007). Although the function of TGFR2 in regeneration of the adult liver has been thoroughly examined (Oe et al., 2004), the function of TGFR2 in the hepatoblast fate decision has not been elucidated.

CCAAT/enhancer binding protein (c/EBP) transcription factors play decisive roles in the differentiation of various cell types, including hepatocytes (Tomizawa et al., 1998; Yamasaki et al., 2006). The analysis of c/EBP α (*Cebpa*) knockout mice has shown that many abnormal pseudoglandular structures, which co-express antigens specific for both hepatocytes and cholangiocytes, are present in the liver parenchyma (Tomizawa et al., 1998). These data demonstrated that c/EBP α plays an important role in hepatocyte differentiation. It is also known that the suppression of c/EBP α expression in periportal hepatoblasts stimulates cholangiocyte differentiation (Yamasaki et al., 2006). Although the function of c/EBP α in liver development is well known, the relationship between TGF β signaling and c/EBP α -mediated transcriptional regulation in the hepatoblast fate decision is poorly understood. c/EBP β is also known to be an important factor for liver function (Chen et al., 2000), although the function of c/EBP β in the cell fate decision of hepatoblasts is not well known. c/EBP α and c/EBP β bind to the same DNA binding site. However, the promoter activity of hepatocyte-specific genes, such as those encoding hepatocyte nuclear factor 6 (HNF6, also known as ONECUT1) and UGT2B1,

¹Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan. ²Laboratory of Hepatocyte Differentiation, National Institute of Biomedical Innovation, Osaka 567-0085, Japan. ³IPS Cell-based Research Project on Hepatic Toxicity and Metabolism, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan. ⁴Laboratory of Stem Cell Regulation, National Institute of Biomedical Innovation, Osaka 567-0085, Japan. ⁵Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo 162-8666, Japan. ⁶Pharmaceutical Research and Technology Institute, Kinki University, Osaka 577-8502, Japan. ⁷Laboratory of Embryonic Stem Cell Cultures, Department of Disease Bioresearch, National Institute of Biomedical Innovation, Osaka 567-0085, Japan. ⁸Department of Embryonic Stem Cell Research, Field of Stem Cell Research, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan. ⁹The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka 565-0871, Japan.

*Author for correspondence (mizuguch@phs.osaka-u.ac.jp)

Received 27 August 2013; Accepted 3 October 2013

is positively regulated by *c/EBP α* but not *c/EBP β* (Hansen et al., 1998; Plumb-Rudewicz et al., 2004), suggesting that the functions of *c/EBP α* and *c/EBP β* in the hepatoblast fate decision might be different.

In the present study, we first examined the function of TGFBR2 in the hepatoblast fate decision using hESC-derived hepatoblast-like cells, which have the ability to self-replicate, differentiate into both hepatocyte and cholangiocyte lineages, and repopulate the liver of carbon tetrachloride (CCl₄)-treated immunodeficient mice. *In vitro* gain- and loss-of-function analyses and *in vivo* transplantation analysis were performed. Next, we investigated how TGFBR2 expression is regulated in the hepatoblast fate decision. Finally, we examined whether our findings could be reproduced in delta-like 1 homolog (Dlk1)-positive hepatoblasts obtained from the liver of E13.5 mice. To the best of our knowledge, this study provides the first evidence of *c/EBP*-mediated regulation of TGFBR2 expression in the human hepatoblast fate decision.

RESULTS

Hepatoblast-like cells are generated from hESCs

First, we investigated whether the hepatoblast-like cells (HBCs), which were differentiated from hESCs as described in supplementary material Fig. S1A, have similar characteristics to human hepatoblasts. We recently found that hESC-derived HBCs could be purified and maintained on human laminin 111 (LN111)-coated dishes (Takayama et al., 2013). The long-term cultured HBC population (HBCs passaged more than three times were used in this study) were nearly homogeneous and expressed human hepatoblast markers such as alpha-fetoprotein (AFP), albumin (ALB), cytokeratin 19 (CK19, also known as KRT19) and EPCAM (Schmelzer et al., 2007) (supplementary material Fig. S1B). In addition, most of the colonies observed on human LN111-coated plates were ALB and CK19 double positive, although a few colonies were ALB single positive, CK19 single positive, or ALB and CK19 double negative (supplementary material Fig. S1C). To examine the hepatocyte differentiation capacity of the HBCs *in vivo*, these cells were transplanted into CCl₄-treated immunodeficient mice. The hepatocyte functionality of the transplanted cells was assessed by measuring secreted human ALB levels in the recipient mice (supplementary material Fig. S1D). Human ALB serum was detected in the mice that were transplanted with the HBCs, but not in the control mice. These results demonstrated that the HBCs generated from hESCs have similar characteristics to human hepatoblasts and would therefore provide a valuable tool to investigate the mechanisms of human liver development. In the present study, HBCs generated from hESCs were used to elucidate the mechanisms of the hepatoblast fate decision.

TGFBR2 expression is decreased in hepatocyte differentiation but increased in cholangiocyte differentiation

The HBCs used in this study have the ability to differentiate into both hepatocyte-like cells [cytochrome P450 3A4 (CYP3A4) positive; Fig. 1B] and cholangiocyte-like cells (CK19 positive; Fig. 1C) (the protocols are described in Fig. 1A). Because the expression pattern of TGFBR2 during differentiation from hepatoblasts is not well known, we examined it in hepatocyte and cholangiocyte differentiation from HBCs. *TGFBR2* was downregulated during hepatocyte differentiation from HBCs (Fig. 1D), but upregulated in cholangiocyte differentiation from HBCs (Fig. 1E). After the HBCs were cultured on Matrigel, the cells were fractionated into three populations according to the level of TGFBR2 expression (TGFBR2-negative, -lo or -hi; Fig. 1F). The

HBC-derived TGFBR2-lo cells strongly expressed *α AT* and *CYP3A4* (hepatocyte markers), whereas the HBC-derived TGFBR2-hi cells strongly expressed *SOX9* and integrin β 4 (*ITGB4*) (cholangiocyte markers). These data suggest that the TGFBR2 expression level is decreased in hepatic differentiation, but increased in biliary differentiation of the HBCs.

The cell fate decision of HBCs is regulated by TGF β signals

To examine the function of TGF β 1, β 2 and β 3 (all of which are ligands of TGFBR2) in the hepatoblast fate decision, HBCs were cultured in medium containing TGF β 1, β 2 or β 3 (Fig. 2A,B). The expression levels of cholangiocyte marker genes were upregulated by addition of TGF β 1 or TGF β 2, but not TGF β 3 (Fig. 2A), whereas those of hepatocyte markers were downregulated by addition of TGF β 1 or TGF β 2 (Fig. 2B). To ascertain that TGFBR2 is also important in the hepatoblast fate decision, HBCs were cultured in medium containing SB-431542, which inhibits TGF β signaling (Fig. 2C,D). Hepatocyte marker genes were upregulated by inhibition of TGF β signaling (Fig. 2C), whereas cholangiocyte markers were downregulated (Fig. 2D). To confirm the function of TGF β 1, β 2 and β 3 in the hepatoblast fate decision, colony assays of the HBCs were performed in the presence or absence of TGF β 1, β 2 or β 3 (Fig. 2E). The number of CK19 single-positive colonies was significantly increased in TGF β 1- or β 2-treated HBCs. By contrast, the number of ALB and CK19 double-positive colonies was reduced in TGF β 1-, β 2- or β 3-treated HBCs. These data indicated that TGF β 1 and β 2 positively regulate the biliary differentiation of HBCs. Taken together, the findings suggested that TGFBR2 might be a key molecule in the regulation of hepato-biliary lineage segregation.

TGFBR2 plays an important role in the cell fate decision of HBCs

To examine whether TGFBR2 plays an important role in the hepatoblast fate decision, *in vitro* gain- and loss-of-function analysis of TGFBR2 was performed in the HBCs. We used siRNA in knockdown experiments (supplementary material Fig. S2) during HBC differentiation on Matrigel. Whereas TGFBR2-suppressing siRNA (si-TGFBR2) transfection upregulated the expression of hepatocyte markers, it downregulated cholangiocyte markers (Fig. 3A). si-TGFBR2 transfection increased the percentage of asialoglycoprotein receptor 1 (ASGR1)-positive hepatocyte-like cells (Fig. 3B). By contrast, it decreased the percentage of aquaporin 1 (AQP1)-positive cholangiocyte-like cells. These results suggest that TGFBR2 knockdown promotes hepatocyte differentiation, whereas it inhibits cholangiocyte differentiation. Next, we used Ad vector to perform efficient transduction into the HBCs (supplementary material Fig. S3) and ascertained *TGFBR2* gene expression in TGFBR2-expressing Ad vector (Ad-TGFBR2)-transduced cells (supplementary material Fig. S4). Ad-TGFBR2 transduction downregulated the expression of hepatocyte markers, whereas it upregulated cholangiocyte markers (Fig. 3C). Ad-TGFBR2 transduction decreased the percentage of ASGR1-positive hepatocyte-like cells but increased the percentage of AQP1-positive cholangiocyte-like cells (Fig. 3D). These results suggest that TGFBR2 overexpression inhibits hepatocyte differentiation, whereas it promotes cholangiocyte differentiation. Taken together, these results suggest that TGFBR2 plays an important role in deciding the differentiation lineage of HBCs.

To investigate whether hepatoblasts would undergo differentiation in a TGFBR2-associated manner *in vivo*, HBCs transfected/transduced with si-control, si-TGFBR2, Ad-LacZ or Ad-




Fig. 1. HBCs can differentiate into both hepatocyte and cholangiocyte lineages. (A) The strategy for hepatocyte and cholangiocyte differentiation from HBCs. (B, C) The HBC-derived hepatocyte-like cells or cholangiocyte-like cells were subjected to immunostaining with anti-CYP3A4 (red, B) or anti-CK19 (green, C) antibodies, respectively. (D, E) Temporal gene expression levels of hepatocyte markers (α AT and CYP3A4) (D) or cholangiocyte markers (SOX9 and integrin β 4) (E) during hepatocyte or cholangiocyte differentiation as measured by real-time RT-PCR. The temporal gene expression of TGFBR2 was also examined. The gene expression levels in HBCs were taken as 1.0. (F) HBCs were cultured on Matrigel for 5 days, and then the expression level of TGFBR2 was examined by FACS analysis. TGFBR2-negative, -lo and -hi populations were collected and real-time RT-PCR analysis was performed to measure the expression levels of hepatocyte markers (α AT and CYP3A4) and cholangiocyte markers (SOX9 and integrin β 4). * P <0.05, ** P <0.01 (compared with 'before sorting'). Error bars indicate s.d. Statistical analysis was performed using the unpaired two-tailed Student's t -test (n =3).

TGFBR2 were transplanted into CCl₄-treated immunodeficient mice (Fig. 3E,F). Although some of the si-control-transfected or Ad-LacZ-transduced HBCs remained as HBCs (HNF4 α and CK19 double positive), most of them showed *in vitro* differentiation toward hepatocyte-like cells (HNF4 α single positive) (Fig. 3E, top row). By contrast, Ad-TGFBR2-transduced HBCs were predominantly committed to cholangiocyte-like cells (CK19 single positive) and si-TGFBR2-transduced HBCs were predominantly committed to hepatocyte-like cells (HNF4 α single positive) (Fig. 3E, bottom row). Ad-TGFBR2 transduction decreased the percentage of HNF4 α -positive hepatocyte-like cells, whereas it increased the percentage of CK19-positive cholangiocyte-like cells (supplementary material Fig. S5). The hepatocyte functionality of the *in vivo* differentiated HBCs was assessed by measuring secreted human ALB levels in the recipient mice (Fig. 3F). Mice that were transplanted with Ad-TGFBR2-transduced HBCs showed lower human ALB serum levels than those transplanted with Ad-LacZ-transduced HBCs, and the mice that were transplanted with si-TGFBR2-transduced HBCs showed higher human ALB serum

levels than those transplanted with si-control-transfected HBCs. These data suggest that cholangiocyte or hepatocyte differentiation was promoted by TGFBR2 overexpression or knockdown, respectively. Thus, based on these data from *in vitro* and *in vivo* experiments, TGFBR2 plays an important role in deciding the differentiation lineage of HBCs.

TGFBR2 promoter activity and expression are negatively regulated by c/EBP α and positively regulated by c/EBP β

A previous study has shown that TGFBR2 expression is upregulated in Hnf6 knockout mice (Clotman et al., 2005), although we confirmed by ChIP assay that HNF6 does not bind to the TGFBR2 promoter region (data not shown). Because c/EBP α is important in the hepatoblast fate decision (Suzuki et al., 2003), we expected that c/EBPs might directly regulate TGFBR2 expression. The TGFBR2 promoter region was analyzed to examine whether TGFBR2 expression is regulated by c/EBPs. Some c/EBP binding sites (supplementary material Fig. S6) were predicted by rVista 2.0 (<http://rvista.dcode.org/>) (Fig. 4A). By performing a ChIP assay, one




Fig. 2. Hepatocyte and cholangiocyte differentiation from HBCs is regulated by TGFβ signaling. (A,B) HBCs were cultured in differentiation hESF-DIF medium containing 10 ng/ml TGFβ1, TGFβ2 or TGFβ3 for 10 days. The expression levels of cholangiocyte (A) and hepatocyte (B) marker genes were measured by real-time RT-PCR. On the y-axis, the gene expression level of cholangiocyte markers in untreated cells (NONE) was taken as 1.0. (C,D) HBCs were cultured in differentiation hESF-DIF medium containing SB-431542 (10 μM) for 10 days. Control cells were treated with solvent only (0.1% DMSO). Expression levels of hepatocyte (C) and cholangiocyte (D) marker genes were measured by real-time RT-PCR. On the y-axis, the gene expression level of hepatocyte markers in untreated cells (control) was taken as 1.0. (E) HBC colony formation assay in the presence or absence of 10 ng/ml TGFβ1, TGFβ2 or TGFβ3. HBCs were plated at 200 cells/cm² on human LN111-coated dishes. The colonies were separated into four groups based on the expression of ALB and CK19: double-negative, ALB negative and CK19 positive, ALB positive and CK19 negative, and double positive. The numbers represent wells in which the colony was observed in three 96-well plates (total 288 wells). Five days after plating, the cells were fixed with 4% PFA and used for double immunostaining. **P*<0.05, ***P*<0.01 (compared with NONE). Error bars indicate s.d. Statistical analysis was performed using the unpaired two-tailed Student's *t*-test (*n*=3).

c/EBP binding site was found in the *TGFBR2* promoter region (Fig. 4B). A reporter assay of the *TGFBR2* promoter region showed that *c/EBPβ* activates *TGFBR2* promoter activity, whereas *c/EBPα* inhibits it (Fig. 4C). In addition, *TGFBR2* expression was downregulated by Ad-*c/EBPα* transduction, whereas *TGFBR2* was upregulated by Ad-*c/EBPβ* transduction in HepG2 cells (*TGFBR2* positive) (Fig. 4D). We ascertained the expression of *c/EBPα* or *c/EBPβ* (*CEBPA* or *CEBPB* – Human Gene Nomenclature Committee) in the Ad-*c/EBPα*- or Ad-*c/EBPβ*-transduced cells, respectively (supplementary material Fig. S4). These results demonstrated that the promoter activity and expression of *TGFBR2* were directly regulated by both *c/EBPα* and *c/EBPβ*.

***c/EBPs* determine the cell fate decision of HBCs via regulation of *TGFBR2* expression**

To elucidate the relationship between *TGFBR2* and *c/EBPs* (*c/EBPα* and *c/EBPβ*) in the hepatoblast fate decision, we first examined the

temporal gene expression patterns of *TGFBR2*, *c/EBPα* and *c/EBPβ* in hepatocyte and cholangiocyte differentiation. During hepatocyte differentiation, *TGFBR2* expression was downregulated, whereas *c/EBPα* was upregulated (supplementary material Fig. S7A, top). During cholangiocyte differentiation, *c/EBPα* was downregulated, whereas *TGFBR2* and *c/EBPβ* were upregulated (supplementary material Fig. S7A, bottom). In addition, the ratio of *c/EBPα* to *c/EBPβ* was significantly increased in hepatocyte differentiation, but significantly reduced in cholangiocyte differentiation (supplementary material Fig. S7B). High-level expression of *c/EBPα* was detected in *TGFBR2*-negative cells, but not in *TGFBR2*-hi cells (supplementary material Fig. S7C). By contrast, high-level expression of *c/EBPβ* was detected in *TGFBR2*-hi cells, but not in *TGFBR2*-negative cells. These results suggest that *TGFBR2* is negatively regulated by *c/EBPα* and positively regulated by *c/EBPβ* in the differentiation model from HBCs as well as in the HepG2 cell line (Fig. 4).




Fig. 3. TGFBR2 regulates bi-directional differentiation of HBCs. (A) HBCs were transfected with 50 nM control siRNA (si-control) or TGFBR2-suppressing siRNA (si-TGFBR2) and cultured in differentiation hESF-DIF medium for 10 days. The expression levels of hepatocyte (α AT and CYP3A4) or cholangiocyte (SOX9 and integrin β 4) markers were measured by real-time RT-PCR. On the y-axis, the gene expression level in HBCs was taken as 1.0. (B) On day 10 after siRNA transfection, the efficiency of hepatocyte or cholangiocyte differentiation was measured by estimating the percentage of ASGR1-positive or AQP1-positive cells, respectively, by FACS analysis. (C) HBCs were transfected with 3000 VPs/cell of Ad-LacZ or Ad-TGFBR2 for 1.5 hours and cultured in differentiation hESF-DIF medium for 10 days. Expression levels of hepatocyte or cholangiocyte marker genes were measured by real-time RT-PCR. On the y-axis, gene expression levels in the HBCs was taken as 1.0. (D) On day 10 after Ad vector transduction, the efficiency of hepatocyte or cholangiocyte differentiation was measured by estimating the percentage of ASGR1-positive or AQP1-positive cells, respectively, by FACS analysis. (E, F) The si-control, si-TGFBR2, Ad-LacZ- or Ad-TGFBR2-transfected/transduced HBCs (1.0×10^6 cells) were transplanted into CCl₄-treated (2 mg/kg) Rag2^{fl/fl}/Irf3^{fl/fl} double-knockout mice by intrasplenic injection. (E) Expression of human HNF4 α (red) and CK19 (green) was examined by double immunohistochemistry 2 weeks after transplantation. Nuclei were counterstained with DAPI (blue). (F) Levels of human ALB in recipient mouse serum were measured 2 weeks after transplantation. * $P < 0.05$, ** $P < 0.01$ (compared with Ad-LacZ-transduced or si-control-transfected cells). Error bars indicate s.d. Statistical analysis was performed using the unpaired two-tailed Student's *t*-test ($n = 3$).

ChIP experiments showed that *c/EBP α* or *c/EBP β* is recruited to the *TGFBR2* promoter region containing the *c/EBP* binding site in hepatocyte-like cells or cholangiocyte-like cells, respectively (Fig. 5A), suggesting that *c/EBP α* and *c/EBP β* oppositely regulate *TGFBR2* promoter activity in the differentiation from HBCs. We confirmed that *c/EBP α* or *c/EBP β* was mainly recruited to the *TGFBR2* promoter region containing the *c/EBP* binding site in TGFBR-negative or TGFBR2-positive cells, respectively (supplementary material Fig. S7D). Taken together, we concluded that *c/EBP α* and *c/EBP β* are able to regulate the cell fate decision of HBCs via regulation of *TGFBR2* expression. During differentiation from HBCs, *TGFBR2* expression was negatively regulated by *c/EBP α* and positively regulated by *c/EBP β* (Fig. 5B). To examine whether *c/EBP α* or *c/EBP β* could regulate the differentiation from HBCs, *in vitro* gain- and loss-of-function analyses were performed. si-*c/EBP α* transfection downregulated hepatocyte marker gene expression, whereas it upregulated cholangiocyte marker genes (Fig. 5C). By contrast, si-*c/EBP β* transfection upregulated hepatocyte marker and downregulated cholangiocyte marker gene expression (Fig. 5C). In accordance, Ad-*c/EBP α* transduction upregulated hepatocyte marker genes and downregulated cholangiocyte markers (Fig. 5D), whereas Ad-

c/EBP β transduction downregulated hepatocyte markers and upregulated cholangiocyte marker genes. Promotion of hepatocyte differentiation by Ad-*c/EBP α* transduction was inhibited by Ad-TGFBR2 transduction, whereas inhibition of cholangiocyte differentiation by Ad-*c/EBP α* transduction was rescued by Ad-TGFBR2 transduction (Fig. 5E). In addition, promotion of hepatocyte differentiation by si-*c/EBP β* transfection was inhibited by Ad-TGFBR2 transduction, whereas inhibition of cholangiocyte differentiation by si-*c/EBP β* transfection was rescued by Ad-TGFBR2 transduction (Fig. 5F). We further confirmed that inhibition of hepatocyte differentiation by si-*c/EBP α* -transfection was rescued by si-TGFBR2 transfection (supplementary material Fig. S8). Taken together, these results led us to conclude that *c/EBP α* and *c/EBP β* could determine the cell fate of HBCs by negatively and positively regulating *TGFBR2* expression, respectively (supplementary material Fig. S9).

***c/EBPs* organize the differentiation of fetal mouse hepatoblasts through regulation of *TGFBR2* expression**

We have demonstrated that *c/EBPs* may determine the HBC fate decision via regulation of the expression level of *TGFBR2*. To examine whether our findings could be replicated in native liver




Fig. 4. *TGFBR2* promoter activity and expression are negatively regulated by *c/EBPα* and positively regulated by *c/EBPβ*. (A) Candidate *c/EBP* binding sites (hatched boxes) in the *TGFBR2* promoter region as predicted using rVista 2.0 (see supplementary material Fig. S7). (B) hESCs (H9 cells) were differentiated into hepatoblasts and then a ChIP assay performed. The antibodies and primers employed are summarized in supplementary material Tables S1 and S4. (C) HEK293 cells were transfected with firefly luciferase (Luc) expression plasmids containing the promoter region of *TGFBR2*. In addition, empty plasmid (pHMEF5), *c/EBPα* expression plasmid (pHMEF5-*c/EBPα*) or *c/EBPβ* expression plasmid (pHMEF5-*c/EBPβ*) was transfected. After 36 hours, a dual luciferase assay was performed. Base pair positions are relative to the translation start site (+1). (D) HepG2 cells (*TGFBR2*-positive cells) were transfected with 3000 VPs/cell of Ad-LacZ, Ad-*c/EBPα* or Ad-*c/EBPβ* for 1.5 hours and cultured for 48 hours. The expression level of *TGFBR2* in HepG2 cells was measured by real-time RT-PCR. On the y-axis, the gene expression level in Ad-LacZ-transduced cells was taken as 1.0. **P* < 0.05, ***P* < 0.01. Error bars indicate s.d. Statistical analysis was performed using the unpaired two-tailed Student's *t*-test (*n* = 3).

development, fetal hepatoblasts were purified from E13.5 mice. The gene expression level of *TGFBR2* in fetal mouse hepatoblasts was negatively or positively regulated by *c/EBPα* or *c/EBPβ*, respectively (Fig. 6A,B). The promotion of hepatocyte differentiation by Ad-*c/EBPα* transduction was inhibited by Ad-*TGFBR2* transduction, whereas the inhibition of cholangiocyte differentiation by Ad-*c/EBPα* transduction was rescued by Ad-*TGFBR2* transduction (Fig. 6C). In addition, the promotion of hepatocyte differentiation by si-*c/EBPβ* transfection was inhibited by Ad-*TGFBR2* transduction, whereas the inhibition of cholangiocyte differentiation by si-*c/EBPβ* transfection was rescued by Ad-*TGFBR2* transduction (Fig. 6D). Taken together, these results led us to conclude that *c/EBPα* and *c/EBPβ* could determine the cell fate of fetal mouse hepatoblasts by negatively and positively regulating *TGFBR2* expression, respectively. Our *in vitro* differentiation system could also prove useful in elucidating the molecular mechanisms of human liver development.

DISCUSSION

The purpose of this study was to better understand the molecular mechanisms of the hepatoblast fate decision in humans. To elucidate the molecular mechanisms of liver development, both conditional knockout mouse models and cell culture systems are useful. For example, DeLaForest et al. demonstrated the role of HNF4α in hepatocyte differentiation using hESC culture systems (DeLaForest et al., 2011). The technology for inducing hepatocyte differentiation from hESCs has recently been dramatically advanced (Takayama et al., 2012a). Because it is possible to generate functional HBCs from hESCs, which can self-replicate and differentiate into both hepatocyte and cholangiocyte lineages (supplementary material Fig. S1 and Fig. 1), the differentiation model of HBCs generated from hESCs should provide a powerful tool for analyzing the molecular mechanisms of human liver development.

In this study, the molecular mechanisms of the hepatoblast fate decision were elucidated using hESC culture systems. HBCs cultured on human LN111 expressed hepatoblast markers (supplementary material Fig. S1) and had the ability to differentiate into both hepatocyte-like cells and cholangiocyte-like cells (Fig. 1). Because a previous study showed that low and high concentrations of TGFβ were required for hepatocyte and cholangiocyte differentiation, respectively (Clotman et al., 2005), we expected that *TGFBR2* might contribute to the hepatoblast fate decision. Although TGFβ1, β2 and β3 are all ligands of *TGFBR2*, TGFβ3 did not promote cholangiocyte differentiation (Fig. 2). This might have been because only TGFβ3 is unable to upregulate the expression of *SOX9*, which is the key factor in bile duct development *in vivo* and cholangiocyte differentiation *in vitro* (Antoniou et al., 2009). We examined the function of *TGFBR2* in the hepatoblast fate decision, and found that its overexpression promoted cholangiocyte differentiation, whereas *TGFBR2* knockdown promoted hepatocyte differentiation (Fig. 3). Although an exogenous TGFβ ligand was not added to the differentiation medium, the endogenous TGFβ ligand present in Matrigel, which was used in our differentiation protocol, might have bound to *TGFBR2*. It might also be that the cells committed to the biliary lineage express TGFβ, as a previous study showed that bile duct epithelial cells express TGFβ (Lewindon et al., 2002).

To examine the molecular mechanism regulating *TGFBR2* expression, the *TGFBR2* promoter region was analyzed (Fig. 4). *TGFBR2* promoter activity was negatively regulated by *c/EBPα* and positively regulated by *c/EBPβ*. *c/EBPα* overexpression downregulated *TGFBR2* promoter activity in spite of the fact that *c/EBPα* protein has no repression domain (Yoshida et al., 2006). CTBP1 and CTBP2 (Vernochet et al., 2009) are known to be co-repressors of *c/EBPα*, and as such constitute candidate co-repressors recruited to the *c/EBP* binding site in the *TGFBR2* promoter region.




Fig. 5. *c/EBPα* and *c/EBPβ* promote hepatocyte and cholangiocyte differentiation by regulating *TGFBR2* expression, respectively. (A) HBCs were differentiated into hepatocyte-like cells or cholangiocyte-like cells according to the scheme outlined in Fig. 1A. On day 10 after hepatocyte or cholangiocyte differentiation, recruitment of *c/EBPα* or *c/EBPβ* to the *TGFBR2* promoter region was examined by ChIP assay. (B–D) HBCs were transfected with 50 nM si-control, si-c/EBPα or si-c/EBPβ and cultured in differentiation hESF-DIF medium for 10 days (B left, C). The expression levels of *TGFBR2* and hepatocyte and cholangiocyte markers were then measured by real-time RT-PCR. (B right, D) HBCs were transfected with 3000 VPs/cell of Ad-LacZ, Ad-c/EBPα or Ad-c/EBPβ for 1.5 hours and cultured in differentiation hESF-DIF medium for 10 days. The expression levels of *TGFBR2* and hepatocyte and cholangiocyte markers were then measured by real-time RT-PCR. On the y-axis, the gene expression level in the si-control-transfected or Ad-LacZ-transduced cells was taken as 1.0 in B, and levels in HBCs were taken as 1.0 in C and D. (E) HBCs were transfected with 3000 VPs/cell each of Ad-LacZ + Ad-LacZ, Ad-c/EBPα + Ad-LacZ, or Ad-c/EBPα + Ad-TGFBR2 for 1.5 hours and cultured in differentiation hESF-DIF medium for 10 days. The efficiency of hepatocyte or cholangiocyte differentiation was measured by estimating the percentage of ASGR1-positive or AQP1-positive cells, respectively, by FACS analysis. (F) HBCs were transfected with 3000 VPs/cell of Ad-LacZ or Ad-TGFBR2 and then transfected with 50 nM si-control or si-c/EBPβ and cultured in hESF-DIF medium for 10 days. The efficiency of hepatocyte or cholangiocyte differentiation was measured by estimating the percentage of ASGR1-positive or AQP1-positive cells, respectively, by FACS analysis. * $P < 0.05$, ** $P < 0.01$. Error bars indicate s.d. Statistical analysis was performed using the unpaired two-tailed Student's *t*-test ($n = 3$).

Proteome analysis of *c/EBPα* would provide an opportunity to identify the co-repressor of *c/EBPα*. Because large numbers of nearly homogeneous hepatoblasts can be differentiated from hESCs, as compared with the isolation of fetal liver hepatoblasts, hepatocyte differentiation technology from hESCs might prove useful in proteome analysis.

We found that Ad-c/EBPα transduction could promote hepatocyte differentiation by suppressing *TGFBR2* expression (Fig. 5). Our findings might thus provide a detailed explanation of the phenotype of *c/EBPα* knockout mice; that is, hepatocyte differentiation is

inhibited and cholangiocyte differentiation is promoted in these mice (Yamasaki et al., 2006). We also found that Ad-c/EBPβ transduction could promote cholangiocyte differentiation by enhancing *TGFBR2* expression. Because both *c/EBPα* and *c/EBPβ* can bind to the same binding site, reciprocal competition for binding is likely to be influenced by regulating *c/EBPα* or *c/EBPβ* expression. Therefore, the expression ratio between *c/EBPα* and *c/EBPβ* might determine the cell fate of hepatoblasts by regulating the expression level of *TGFBR2*. We confirmed that our findings could be reproduced in fetal mouse hepatoblasts (Fig. 6). Because a previous study had




Fig. 6. c/EBPs control the differentiation of fetal mouse hepatoblasts through regulation of TGFBR2 expression. Fetal mouse hepatoblasts (Dlk1-positive cells; the purity was over 98%) were sorted from E13.5 mouse liver. (A) Fetal mouse hepatoblasts were transfected with 50 nM si-control, si-c/EBP α or si-c/EBP β and cultured for 5 days. The expression of *TGFBR2* was measured by real-time RT-PCR. (B) Fetal mouse hepatoblasts were transduced with 3000 VPs/cell of Ad-LacZ, Ad-c/EBP α or Ad-c/EBP β for 1.5 hours and cultured for 5 days. The expression of *TGFBR2* was measured by real-time RT-PCR. On the y-axis, the gene expression level in the si-control-transfected cells or Ad-LacZ-transduced cells was taken as 1.0. (C) Fetal mouse hepatoblasts were transduced with 3000 VPs/cell each of Ad-LacZ + Ad-LacZ, Ad-c/EBP α + Ad-LacZ, or Ad-c/EBP α + Ad-TGFBR2 for 1.5 hours and cultured for 5 days. On day 5, the expression levels of hepatocyte (α AT and *Cyp7a1*) and cholangiocyte (*Aqp1* and integrin β 4) markers were measured by real-time RT-PCR. (D) Fetal mouse hepatoblasts were transduced with 3000 VPs/cell of Ad-LacZ or Ad-TGFBR2 and then transfected with 50 nM si-control or si-c/EBP β and cultured for 5 days. On day 5, the gene levels of hepatocyte (α AT and *Cyp7a1*) and cholangiocyte (*Aqp1* and integrin β 4) markers were measured by real-time RT-PCR. On the y-axis, the gene expression level in the si-control-transfected or Ad-LacZ-transduced cells was taken as 1.0. * P <0.05, ** P <0.01. Error bars indicate s.d. Statistical analysis was performed using the unpaired two-tailed Student's *t*-test ($n=3$).

shown that the addition of hepatocyte growth factor (HGF) to hepatoblasts upregulated the expression of *c/EBP α* and downregulated the expression of *c/EBP β* (Suzuki et al., 2003), the ratio between *c/EBP α* and *c/EBP β* might be determined by HGF during hepatocyte differentiation.

In this study, we have identified for the first time that *TGFBR2* is a target of *c/EBPs* in the hepatoblast fate decision (supplementary material Fig. S9). *c/EBP α* promotes hepatocyte differentiation by downregulating the expression of *TGFBR2*, whereas *c/EBP β*

promotes cholangiocyte differentiation by upregulating *TGFBR2* expression. This study might have revealed a molecular mechanism underlying the lineage commitment of human hepatoblasts controlled by a gradient of TGF β signaling. We believe that similar procedures that adopt the model of human pluripotent stem cell (including human iPS cell) differentiation will be used not only for the elucidation of molecular mechanisms underlying human hepatocyte and biliary differentiation but also for investigating the causes of congenital anomalies of the human liver and biliary tract.

MATERIALS AND METHODS

Ad vectors

Ad vectors were constructed by an improved *in vitro* ligation method (Mizuguchi and Kay, 1998; Mizuguchi and Kay, 1999). The human *c/EBP α* and *c/EBP β* genes (accession numbers NM_004364 and NM_005194, respectively) were amplified by PCR using the following primers: *c/EBP α* , Fwd 5'-GCTCTAGATGCCGGGAGAACTCTAACTC-3' and Rev 5'-GCGGTACCAAACCACTCCCTGGGTCC-3'; *c/EBP β* , Fwd 5'-GCATCTAGATTTCATGCAACGCCTGGTG-3' and Rev 5'-ATAGGTACCTAAAATTACCGACGGGCTCC-3'. The human *TGFBR2* gene was purchased from Addgene (plasmid 16622). The human *c/EBP α* , *c/EBP β* or *TGFBR2* gene was inserted into pBSKII (Invitrogen), resulting in pBSKII-*c/EBP α* , -*c/EBP β* or -*TGFBR2*. Then, human *c/EBP α* , *c/EBP β* or *TGFBR2* was inserted into pMIEF5 (Kawabata et al., 2005), which contains the human elongation factor 1 α (*EF1 α* , also known as *EEF1A1*) promoter, resulting in pMIEF5-*c/EBP α* , -*c/EBP β* or -*TGFBR2*. pMIEF5-*c/EBP α* , -*c/EBP β* or -*TGFBR2* was digested with *I-CeuI/PI-SceI* and ligated into *I-CeuI/PI-SceI*-digested pAdHM41-K7 (Koizumi et al., 2003), resulting in pAd-*c/EBP α* , -*c/EBP β* or -*TGFBR2*. The human *EF1 α* promoter-driven *lacZ*- or *FOXA2*-expressing Ad vectors (Ad-LacZ or Ad-*FOXA2*, respectively) were constructed previously (Takayama et al., 2012b; Tashiro et al., 2008). All Ad vectors contain a stretch of lysine residues (K7) in the C-terminal region of the fiber knob for more efficient transduction of hESCs, definitive endoderm cells and HBCs, in which transfection efficiency was almost 100%, and the Ad vectors were purified as described previously (Takayama et al., 2012a; Takayama et al., 2011). The vector particle (VP) titer was determined by a spectrophotometric method (Maizel et al., 1968).

hESC culture

The H9 hESC line (WiCell Research Institute) was maintained on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts (Merck Millipore) in ReproStem medium (ReproCELL) supplemented with 5 ng/ml FGF2 (Katayama Kagaku Kogyo). H9 was used following the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science and Technology of Japan and the study was approved by the Independent Ethics Committee.

Generation and maintenance of hESC-derived HBCs

Before the initiation of cellular differentiation, the hESC medium was exchanged for a defined serum-free medium, hESF9, and cultured as previously reported (Furue et al., 2008). The differentiation protocol for the induction of definitive endoderm cells and HBCs was based on our previous reports with some modifications (Takayama et al., 2012a; Takayama et al., 2012b; Takayama et al., 2011). Briefly, in mesendoderm differentiation, hESCs were cultured for 2 days on Matrigel Matrix (BD Biosciences) in differentiation hESF-DIF medium, which contains 100 ng/ml activin A (R&D Systems); hESF-DIF medium was purchased from Cell Science & Technology Institute; differentiation hESF-DIF medium was supplemented with 10 μ g/ml human recombinant insulin, 5 μ g/ml human apotransferrin, 10 μ M 2-mercaptoethanol, 10 μ M ethanolamine, 10 μ M sodium selenite, 0.5 mg/ml bovine fatty acid-free serum albumin (all from Sigma) and 1 \times B27 Supplement (without vitamin A; Invitrogen). To generate definitive endoderm cells, the mesendoderm cells were transduced with 3000 VPs/cell of *FOXA2*-expressing Ad vector (Ad-*FOXA2*) for 1.5 hours on day 2 and cultured until day 6 on Matrigel in differentiation hESF-DIF medium supplemented with 100 ng/ml activin A. For induction of the HBCs, the

definitive endoderm cells were cultured for 3 days on Matrigel in differentiation hESF-DIF medium supplemented with 20 ng/ml BMP4 (R&D Systems) and 20 ng/ml FGF4 (R&D Systems). Transient overexpression of FOXA2 in the mesendoderm cells is not necessary for establishing HBCs, but it is helpful for efficient generation of the HBCs. The HBCs were first purified from the hESC-derived cells (day 9) by selecting attached cells on a human recombinant LN111 (BioLamina)-coated dish 15 minutes after plating (Takayama et al., 2013). The HBCs were cultured on a human LN111-coated dish (2.0×10^4 cells/cm²) in maintenance DMEM/F12 medium [DMEM/F12 medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS), $1 \times$ insulin/transferrin/selenium, 10 mM nicotinamide, 0.1 μ M dexamethasone (DEX) (Sigma), 20 mM HEPES, 25 mM NaHCO₃, 2 mM L-glutamine, and penicillin/streptomycin] which contained 40 ng/ml HGF (R&D Systems) and 20 ng/ml epidermal growth factors (EGF) (R&D Systems). The medium was refreshed every day. The HBCs were dissociated with Accutase (Millipore) into single cells, and subcultured every 6 or 7 days. The HBCs used in this study were passaged more than three times.

In vitro hepatocyte and cholangiocyte differentiation

To induce hepatocyte differentiation, the HBCs were cultured on a Matrigel-coated dish (7.5×10^4 cells/cm²) in Hepatocyte Culture Medium (HCM without EGF; Lonza) supplemented with 20 ng/ml HGF, 20 ng/ml Oncostatin M (OsM) (R&D Systems) and 1 μ M DEX. To induce cholangiocyte differentiation, the HBCs were cultured in collagen gel. To establish collagen gel plates, 500 μ l collagen gel solution [400 μ l type I-A collagen (Nitta gelatin), 50 μ l $10 \times$ DMEM and 50 μ l 200 mM HEPES buffer containing 2.2% NaHCO₃ and 0.05 M NaOH] was added to each well, and then the plates were incubated at 37°C for 30 minutes. The HBCs (5×10^4 cells) were resuspended in 500 μ l differentiation DMEM/F12 medium [DMEM/F12 medium supplemented with 20 mM HEPES, 2 mM L-glutamine, 100 ng/ml EGF and 40 ng/ml ILGF2 (IGF2)], and then mixed with 500 μ l of the collagen gel solution and plated onto the basal layer of collagen. After 30 minutes, 2 ml differentiation DMEM/F12 medium was added to the well.

Inhibition of TGF β signaling

SB-431542 (Santa Cruz Biotechnology), which is a small molecule that acts as a selective inhibitor of activin receptor-like kinase (ALK) receptors [ALK4, ALK5 and ALK7 (also known as ACVR1B, TGFBR1 and ACVR1C)], was used to inhibit TGF β signaling in HBCs.

Flow cytometry

Single-cell suspensions of hESC-derived cells were fixed with 2% paraformaldehyde (PFA) at 4°C for 20 minutes, and then incubated with primary antibody (supplementary material Table S1) followed by secondary antibody (supplementary material Table S2). Flow cytometry analysis was performed using a FACS LSR Fortessa flow cytometer (BD Biosciences). Cell sorting was performed using a FACS Aria (BD Biosciences).

RNA isolation and reverse transcription (RT)-PCR

Total RNA was isolated from hESCs and their derivatives using ISOGENE (Nippon Gene). cDNA was synthesized using 500 ng total RNA with the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Real-time RT-PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems) using an Applied Biosystems StemOnePlus real-time PCR system. Relative quantification was performed against a standard curve and the values were normalized against the input determined for the housekeeping gene *GAPDH*. Primers are described in supplementary material Table S3.

Immunohistochemistry

Cells were fixed with 4% PFA. After incubation with 0.1% Triton X-100 (Wako), blocking with Blocking One (Nakalai Tesque) or PBS containing 2% FBS, 2% BSA and 0.1% Triton X-100, the cells were incubated with primary antibody (supplementary material Table S1) at 4°C overnight, followed by secondary antibody (supplementary material Table S2) at room

temperature for 1 hour. Immunopositive cells were counted in at least eight randomly chosen fields.

HBC colony formation assay

For the colony formation assay, HBCs were cultured at a low density (200 cells/cm²) on a human LN111-coated dish in maintenance DMEM/F12 medium supplemented with 25 μ M LY-27632 (ROCK inhibitor; Millipore).

Transplantation of clonally derived HBCs

Clonally derived HBCs were dissociated using Accutase and then suspended in maintenance DMEM/F12 medium without serum. The HBCs (1×10^6 cells) were transplanted 24 hours after administration of CCl₄ (2 mg/kg) by intrasplenic injection into 8- to 10-week-old *Rag2/Il2rg* double-knockout mice. Recipient mouse livers and blood were harvested 2 weeks after transplantation. Grafts were fixed with 4% PFA and processed for immunohistochemistry. Serum was extracted and subjected to ELISA. All animal experiments were conducted in accordance with institutional guidelines.

ELISA

Levels of human ALB in mouse serum were examined by ELISA using kits from Bethyl Laboratories according to the manufacturer's instructions.

Culture of mouse Dlk1⁺ cells

Dlk1⁺ hepatoblasts were isolated from E13.5 mouse livers using anti-mouse Dlk1 monoclonal antibody (MBL International Corporation, D187-4) as described previously (Tanimizu et al., 2003). Dlk1⁺ cells were resuspended in DMEM/F12 (Sigma) containing 10% FBS, $1 \times$ insulin/transferrin/selenium (ITS), 10 mM nicotinamide (Wako), 0.1 μ M DEX and 5 mM L-glutamine. Cells were plated on laminin-coated dishes and cultured in medium containing 20 ng/ml HGF, EGF and 25 μ M LY-27632 (ROCK inhibitor).

lacZ assay

Hepatoblasts were transduced with Ad-LacZ at 3000 VPs/cell for 1.5 hours. The day after transduction (day 10), 5-bromo-4-chloro-3-indolyl β -D-galactopyranoside (X-Gal) staining was performed as described previously (Kawabata et al., 2005).

Reporter assays

The effects of *c/EBP α* or *c/EBP β* overexpression on *TGFBR2* promoter activity were examined using a reporter assay. An 8 kb fragment of the 5' flanking region of the *TGFBR2* gene was amplified by PCR using the following primers: Fwd, 5'-CCGAGCTCATGTTTGATGAAGTGCTAGCTTCCAAGG-3'; Rev, 5'-GGCTCGAGCCTCGACGTCCAGCCCCCT-3'. The fragment was inserted into the *SacI/XhoI* sites of pGL3-basic (Promega), resulting in a pGL3-*TGFBR2* promoter region (pGL3-TGFBR2-PR). To generate a *TGFBR2* promoter region containing mutations in the *c/EBP* binding site, the following primers were used in PCR (mutations are indicated by lowercase letters): Fwd, 5'-CACTAGTATTCAgTG-AtCgAAAAATATGG-3'; Rev, 5'-CACTAGTATTCAgTGATcCgAAAAATATGG-3'; this resulted in pGL3-mTGFBR2-PR. HEK293 cells were maintained in DMEM (Wako) supplemented with 10% FBS, penicillin and streptomycin, and 2 mM L-glutamine. In reporter assays, 60 ng pGL3-TGFBR2-PR or pGL3-mTGFBR2-PR was transfected together with 720 ng each expression plasmid (pHMEF5, pHMEF5-*c/EBP α* and pHMEF5-*c/EBP β*) and 60 ng internal control plasmid (pCMV-Renilla luciferase) using Lipofectamine 2000 reagent (Invitrogen). Transfected cells were cultured for 36 hours, and a Dual Luciferase Assay (Promega) was performed according to the manufacturer's instructions.

siRNA-mediated knockdown

Pre-designed siRNAs targeting *c/EBP α* , *c/EBP β* and *TGFBR2* mRNAs were purchased from Thermo Scientific Dharmacon. Cells were transfected with 50 nM siRNA using RNAiMAX (Invitrogen) transfection reagent according to the manufacturer's instructions. As a negative control, we used scrambled siRNA (Qiagen) of a sequence showing no significant similarity to any mammalian gene.

Chromatin immunoprecipitation (ChIP) assay

The ChIP assay kit was purchased from Upstate. Cells were crosslinked using formaldehyde at a final concentration of 1% at 37°C for 10 minutes, and then genomic DNA was fragmented by sonicator. The resulting DNA-protein complexes were immunoprecipitated using the antibodies described in supplementary material Table S1 or control IgG as described in supplementary material Table S2. The precipitated DNA fragments were analyzed by real-time RT-PCR using the primers shown in supplementary material Table S4 to amplify the *TGFBR2* promoter region including the c/EBP binding sites or β -actin locus as a control. The results of quantitative ChIP analysis (Fig. 5A) were expressed as the amount of amplified *TGFBR2* promoter region relative to input DNA taken as 100%.

Statistical analysis

Statistical analysis was performed using an unpaired two-tailed Student's *t*-test. All data are represented as mean \pm s.d. ($n=3$).

Acknowledgements

We thank Natsumi Mimura, Yasuko Hagihara and Hiroko Matsumura for excellent technical support.

Competing interests

The authors declare no competing financial interests.

Author contributions

K. Takayama, K.K. and H.M. developed the concepts or approach; K. Takayama, Y.N., K.O., H.O. and T.Y. performed experiments; K. Takayama, K.K., M.I., K. Tashiro, F.S., T.H., T.O., M.F.K. and H.M. performed data analysis; K. Takayama, K.K. and H.M. prepared or edited the manuscript prior to submission.

Funding

H.M., K.K., M.K.F. and T.H. were supported by grants from the Ministry of Health, Labor, and Welfare of Japan (MEXT). H.M. was also supported by Japan Research Foundation for Clinical Pharmacology, The Uehara Memorial Foundation. K.O. was supported by Special Coordination Funds for Promoting Science and Technology from MEXT. F.S. was supported by Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO). K. Takayama and Y.N. are Research Fellows of the Japan Society for the Promotion of Science.

Supplementary material

Supplementary material available online at <http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.103168/-DC1>

References

- Agarwal, S., Holton, K. L. and Lanza, R. (2008). Efficient differentiation of functional hepatocytes from human embryonic stem cells. *Stem Cells* **26**, 1117-1127.
- Antoniou, A., Raynaud, P., Cordi, S., Zong, Y., Tronche, F., Stanger, B. Z., Jacquemin, P., Pierreux, C. E., Clotman, F. and Lemaigre, F. P. (2009). Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. *Gastroenterology* **136**, 2325-2333.
- Chen, S. S., Chen, J. F., Johnson, P. F., Muppala, V. and Lee, Y. H. (2000). C/EBP β , when expressed from the C/ebp α gene locus, can functionally replace C/EBP α in liver but not in adipose tissue. *Mol. Cell. Biol.* **20**, 7292-7299.
- Clotman, F., Jacquemin, P., Plumb-Rudewicz, N., Pierreux, C. E., Van der Smissen, P., Dietz, H. C., Courtoy, P. J., Rousseau, G. G. and Lemaigre, F. P. (2005). Control of liver cell fate decision by a gradient of TGF β signaling modulated by Onecut transcription factors. *Genes Dev.* **19**, 1849-1854.
- DeLaForest, A., Nagaoka, M., Si-Tayeb, K., Noto, F. K., Konopka, G., Battle, M. A. and Duncan, S. A. (2011). HNF4A is essential for specification of hepatic progenitors from human pluripotent stem cells. *Development* **138**, 4143-4153.
- Furue, M. K., Na, J., Jackson, J. P., Okamoto, T., Jones, M., Baker, D., Hata, R., Moore, H. D., Sato, J. D. and Andrews, P. W. (2008). Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. *Proc. Natl. Acad. Sci. USA* **105**, 13409-13414.
- Hansen, A. J., Lee, Y. H., Sterneck, E., Gonzalez, F. J. and Mackenzie, P. I. (1998). C/EBP α is a regulator of the UDP glucuronosyltransferase UGT2B1 gene. *Mol. Pharmacol.* **53**, 1027-1033.
- Kawabata, K., Sakurai, F., Yamaguchi, T., Hayakawa, T. and Mizuguchi, H. (2005). Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. *Mol. Ther.* **12**, 547-554.
- Kitisin, K., Saha, T., Blake, T., Golestaneh, N., Deng, M., Kim, C., Tang, Y., Shetty, K., Mishra, B. and Mishra, L. (2007). TGF- β signaling in development. *Sci. STKE* **2007**, cm1.
- Koizumi, N., Mizuguchi, H., Utoguchi, N., Watanabe, Y. and Hayakawa, T. (2003). Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. *J. Gene Med.* **5**, 267-276.
- Lewindon, P. J., Pereira, T. N., Hoskins, A. C., Bridle, K. R., Williamson, R. M., Shepherd, R. W. and Ramm, G. A. (2002). The role of hepatic stellate cells and transforming growth factor- β (1) in cystic fibrosis liver disease. *Am. J. Pathol.* **160**, 1705-1715.
- Maizel, J. V., Jr, White, D. O. and Scharff, M. D. (1968). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. *Virology* **36**, 115-125.
- Mizuguchi, H. and Kay, M. A. (1998). Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. *Hum. Gene Ther.* **9**, 2577-2583.
- Mizuguchi, H. and Kay, M. A. (1999). A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. *Hum. Gene Ther.* **10**, 2013-2017.
- Oe, S., Lemmer, E. R., Conner, E. A., Factor, V. M., Levéen, P., Larsson, J., Karlsson, S. and Thorgeirsson, S. S. (2004). Intact signaling by transforming growth factor β is not required for termination of liver regeneration in mice. *Hepatology* **40**, 1098-1105.
- Plumb-Rudewicz, N., Clotman, F., Strick-Marchand, H., Pierreux, C. E., Weiss, M. C., Rousseau, G. G. and Lemaigre, F. P. (2004). Transcription factor HNF-6/OC-1 inhibits the stimulation of the HNF-3 α /Foxa1 gene by TGF- β in mouse liver. *Hepatology* **40**, 1266-1274.
- Schmelzer, E., Zhang, L., Bruce, A., Wauthier, E., Ludlow, J., Yao, H. L., Moss, N., Melhem, A., McClelland, R., Turner, W. et al. (2007). Human hepatic stem cells from fetal and postnatal donors. *J. Exp. Med.* **204**, 1973-1987.
- Suzuki, A., Iwama, A., Miyashita, H., Nakauchi, H. and Taniguchi, H. (2003). Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells. *Development* **130**, 2513-2524.
- Takayama, K., Inamura, M., Kawabata, K., Tashiro, K., Katayama, K., Sakurai, F., Hayakawa, T., Furue, M. K. and Mizuguchi, H. (2011). Efficient and directive generation of two distinct endoderm lineages from human ESCs and iPSCs by differentiation stage-specific SOX17 transduction. *PLoS ONE* **6**, e21780.
- Takayama, K., Inamura, M., Kawabata, K., Katayama, K., Higuchi, M., Tashiro, K., Nonaka, A., Sakurai, F., Hayakawa, T., Furue, M. K. et al. (2012a). Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4 α transduction. *Mol. Ther.* **20**, 127-137.
- Takayama, K., Inamura, M., Kawabata, K., Sugawara, M., Kikuchi, K., Higuchi, M., Nagamoto, Y., Watanabe, H., Tashiro, K., Sakurai, F. et al. (2012b). Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1 α transduction. *J. Hepatol.* **57**, 628-636.
- Takayama, K., Nagamoto, Y., Mimura, N., Tashiro, K., Sakurai, F., Tachibana, M., Hayakawa, T., Kawabata, K. and Mizuguchi, H. (2013). Long-term self-renewal of human ES/iPS-derived hepatoblast-like cells on human laminin 111-coated dishes. *Stem Cell Reports* **1**, 322-335.
- Tanimizu, N., Nishikawa, M., Saito, H., Tsujimura, T. and Miyajima, A. (2003). Isolation of hepatoblasts based on the expression of Dlk/Pref-1. *J. Cell Sci.* **116**, 1775-1786.
- Tashiro, K., Kawabata, K., Sakurai, H., Kurachi, S., Sakurai, F., Yamanishi, K. and Mizuguchi, H. (2008). Efficient adenovirus vector-mediated PPAR γ gene transfer into mouse embryoid bodies promotes adipocyte differentiation. *J. Gene Med.* **10**, 498-507.
- Tomizawa, M., Garfield, S., Factor, V. and Xanthopoulos, K. G. (1998). Hepatocytes deficient in CCAAT/enhancer binding protein alpha (C/EBP α) exhibit both hepatocyte and biliary epithelial cell character. *Biochem. Biophys. Res. Commun.* **249**, 1-5.
- Vernochet, C., Peres, S. B., Davis, K. E., McDonald, M. E., Qiang, L., Wang, H., Scherer, P. E. and Farmer, S. R. (2009). C/EBP α and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor γ agonists. *Mol. Cell. Biol.* **29**, 4714-4728.
- Yamasaki, H., Sada, A., Iwata, T., Niwa, T., Tomizawa, M., Xanthopoulos, K. G., Koike, T. and Shiojiri, N. (2006). Suppression of C/EBP α expression in periportal hepatoblasts may stimulate biliary cell differentiation through increased Hnf6 and Hnf1b expression. *Development* **133**, 4233-4243.
- Yoshida, Y., Hughes, D. E., Rausa, F. M., III, Kim, I. M., Tan, Y., Darlington, G. J. and Costa, R. H. (2006). C/EBP α and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells. *Hepatology* **43**, 276-286.




Fig. S1 The hepatoblast-like cells (HBCs) generated from hESCs were characterized.

(A) hESCs were differentiated into the HBCs via definitive endoderm cells. The HBCs were maintained on human LN111. (B) The expression levels of hepatoblast markers (AFP, ALB, CK19, and EpCAM) in the HBCs were examined by FACS

analysis. (C) Clonal assay of the HBC was performed. The HBCs were plated at a density of 200 cells/cm² on human LN111-coated 96-well plates. The colonies were separated into four groups based on the expression of ALB and CK19 (ALB and CK19 double-negative, ALB negative and CK19 positive, ALB positive and CK19 negative, and ALB and CK19 double-positive groups). The numbers represent wells in which the colony was observed in three 96-well plates (total 288 wells). Five days after plating, the cells were fixed with 4% PFA and used for double immunostaining. Nuclei were counterstained with DAPI (blue). (D) The HBCs were transplanted into CCl₄ (2 mL/kg)-treated Rag2/IL2 receptor gamma double-knockout mice. The human ALB level in recipient mouse serum was measured at 2 weeks after transplantation.